benzyloxyphenyl isocyanate | 76813-81-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: benzyloxyphenyl isocyanate
• 英文别名: 2-benzyloxy-phenyl isocyanate；2-Benzyloxy-phenylisocyanat；2-(benzyloxy)phenyl isocyanate；2-benzyloxyphenylisocyanate；1-(Benzyloxy)-2-isocyanatobenzene；1-isocyanato-2-phenylmethoxybenzene
• CAS: 76813-81-5
• 化学式: C₁₄H₁₁NO₂
• 分子量: 225.247
• InChiKey: IIAJZWIXZYPAKY-UHFFFAOYSA-N

物化性质

• 沸点：
  115 °C(Press: 0.5 Torr)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyloxyphenyl isocyanate 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 1-(2-Hydroxy-phenyl)-3-pyridin-4-yl-urea
  参考文献：
  名称：

  N-Phenyl-N'-pyridinylureas as anticonvulsant agents

  摘要：

  A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.

  DOI：

  10.1021/jm00164a061
• 作为产物：
  描述：

  光气 、 2-苄氧基苯胺 以 二氯甲烷 、 甲苯 为溶剂， 反应 0.17h， 生成 benzyloxyphenyl isocyanate
  参考文献：
  名称：

  5-Hydroxytryptamine (5-HT3) receptor antagonists. 3. Ortho-substituted phenylureas

  摘要：

  A novel series of potent 5-HT3 receptor antagonists, ortho-substituted phenylureas 6a-z, is described in which the 5-membered ring of the previously reported indazoles and indolines has been replaced by an intramolecular hydrogen bond. High potency was found both for carbamate 6a and urea 6b. Granatane 6c was less potent than the equivalent tropane. Phenylurea 11c lacking the ortho substituent was inactive. Whereas further substitution could not be tolerated in the aromatic ring, activity was retained with a range of O-alkyl groups, compounds 6k-t. In addition, good activity was found for ortho ester 6u and sulfonamide 6x. The ortho-substituted phenylureas can therefore be regarded as bioisosteres of the 6,5-heterocycles indole, indazole, and indoline.

  DOI：

  10.1021/jm00169a018

文献信息

• Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06500863B1

  公开（公告）日：2002-12-31

  Novell IL-8 compounds and methods of using them are provided.

  提供了Novell IL-8化合物及其使用方法。
• [EN] FLUOROSULFONYL sEH INHIBITORS<br/>[FR] INHIBITEURS DE SEH SUBSTITUÉS PAR FLUOROSULFONYLE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015188060A1

  公开（公告）日：2015-12-10

  Fluorosulfonyl-substituted sEH inhibitors are compounds represented by Formula (I): wherein R1 is selected from the group consisting of alkyl, heteroalkyi, C5-C12 cycloalkyi, C5-C12 cycloalkylalkyi, C5-C12 cycloalkylheteroalkyi, arylalkyi, arylheteroalkyi, aryl, and heteroaryl; and R1 can be substituted or unsubstituted; P1 is a primary pharmacophore; P2 is a secondary pharmacophore; P3 is a tertiary pharmacophore; and L1 and L2 are linking groups. The subscript m has a value of 0 or 1; n has a value of 0 or 1; and the compound of Formula (I) includes at least one S02F ("fluorosulfonyl") group covalently bonded thereto.

  氟磺酰基取代的sEH抑制剂是由式(I)代表的化合物：其中R1选自烷基、杂原烷基、C5-C12环烷基、C5-C12环烷基烷基、C5-C12环烷基杂原烷基、芳基烷基、芳基杂原烷基、芳基和杂原芳基组成；R1可以是取代或未取代的；P1是一级药效团；P2是二级药效团；P3是三级药效团；L1和L2是连接基。下标m的值为0或1；n的值为0或1；式(I)的化合物至少包含一个与之共价键合的S02F（"氟磺酰基"）基团。
• Aminocarnitine Ureidic Derivatives as Inhibitors of Carnitine Palmitoyltransferase I
  作者：Emanuela Tassoni、Roberto Conti、Grazia Gallo、Silvia Vincenti、Natalina Dell'Uomo、Lucilla Mastrofrancesco、Rita Ricciolini、Walter Cabri、Paolo Carminati、Fabio Giannessi

  DOI：10.1002/cmdc.200900535

  日期：2010.5.3

  Aminocarnitine ureidic derivatives were synthesized and evaluated as liver‐isoform‐selective carnitine palmitoyltransferase (CPT) I inhibitors. The most interesting molecule identified (3), the corresponding phosphonium analogue (4) showed improved efficacy in vitro and in vivo over the previously identified compound 1 (teglicar, ST1326).

  合成了氨基肉碱尿素衍生物，并将其评估为肝异构体选择性肉碱棕榈酰转移酶（CPT）I抑制剂。鉴定出的最有趣的分子（3），相应的phospho类似物（4）在体外和体内均显示出比先前鉴定出的化合物1（teglicar，ST1326）更高的功效。
• [EN] HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS<br/>[FR] SULFONAMIDES HYDROXYDIPHENYLUREE ANTAGONISTES DU RECEPTEUR D'IL-8
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000035442A1

  公开（公告）日：2000-06-22

  The invention relates to novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy diphenylurea sulfonamides are useful in the treatment of disease states mediated by the chemokine, Interleukin-8.

  该发明涉及新型羟基二苯基脲磺酰胺、其组合物和中间体。该羟基二苯基脲磺酰胺在治疗由趋化因子Interleukin-8介导的疾病状态中具有用途。
• Anthelmintic 1-(substituted phenyl)-3-alkanimidoyl ureas
  申请人：Sterling Drug Inc.

  公开号：US03984467A1

  公开（公告）日：1976-10-05

  The compounds of this invention are novel imidoylureas having anthelmintic activity and imidoylthioureas having antifertility activity. They are prepared by the reaction of appropriate amidines with appropriate isocyanates or isothiocyanates.

  本发明的化合物是具有驱虫活性的新型咪唑脲和具有抗生育活性的咪唑硫脲。它们是通过适当的胺基与适当的异氰酸酯或异硫氰酸酯反应制备而成。